FDA approves first chemoimmunotherapy regimen for patients with relapsed or refractory diffuse large B-cell lymphoma
June 10, 2019 - Today, the U.S. Food and Drug Administration granted accelerated approval to polatuzumab vedotin-piiq, in combination with the chemotherapy bendamustine and a rituximab product (a combination known as “BR”), to treat adult patients with diffuse ...Leggi tutto